These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 35496290)

  • 1. Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.
    Wang C; Yang D; Wang Y; Ni W
    Front Pharmacol; 2022; 13():896971. PubMed ID: 35496290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
    Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
    Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
    Ong'uti S; Czech M; Robilotti E; Holubar M
    Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
    JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
    Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z
    Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.
    Nurjadi D; Kocer K; Chanthalangsy Q; Klein S; Heeg K; Boutin S
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0201121. PubMed ID: 34871093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
    Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
    Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
    Zhang Q; Neidig N; Chu TY; Divoky C; Carpenter J; Lee-Hsiao C; Threatt H; Sultana R; Bush K
    Diagn Microbiol Infect Dis; 2022 May; 103(1):115651. PubMed ID: 35228130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

  • 13. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
    Syed YY
    Drugs; 2021 Sep; 81(13):1559-1571. PubMed ID: 34427896
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.
    Kaye KS; Naas T; Pogue JM; Rossolini GM
    Infect Dis Ther; 2023 Mar; 12(3):777-806. PubMed ID: 36847998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
    Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
    Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany.
    Ghebremedhin B; Ahmad-Nejad P
    Pathogens; 2021 Sep; 10(10):. PubMed ID: 34684208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
    Parsels KA; Mastro KA; Steele JM; Thomas SJ; Kufel WD
    J Antimicrob Chemother; 2021 May; 76(6):1379-1391. PubMed ID: 33532823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.